Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul;49(3):578-587.
doi: 10.4143/crt.2016.001. Epub 2016 Sep 12.

Real-World Treatment Patterns among Patients with Advanced Gastric Cancer in South Korea

Affiliations

Real-World Treatment Patterns among Patients with Advanced Gastric Cancer in South Korea

Gebra Cuyun Carter et al. Cancer Res Treat. 2017 Jul.

Abstract

Purpose: The purpose of this study was to understand patient treatment patterns, outcomes, and healthcare resource use in cases of metastatic and/or locally recurrent, unresectable gastric cancer (MGC) in South Korea.

Materials and methods: Thirty physicians reviewed charts of eligible patients to collect de-identified data. Patients must have received platinum/fluoropyrimidine first-line therapy followed by second-line therapy or best supportive care, had no other primary cancer, and not participated in a clinical trial following MGC diagnosis. Data were summarized using descriptive statistics. Kaplan-Meier analysis was used to describe survival.

Results: Of 198 patients, 73.7% were male, 78.3% were diagnosed with MGC after age 55 (mean, 61.3 years), and 47.0% were current or former smokers. The majority of tumorswere located in the antrum/pylorus (51.5%). Metastatic sites most often occurred in the peritoneum (53.5%), lymph nodes (47.5%), and liver (38.9%). At diagnosis, the mean Charlson comorbidity indexwas 0.4 (standard deviation, 0.6). The most common comorbidities were chronic gastritis (22.7%) and cardiovascular disease (18.7%). Most patients (80.3%) received second-line treatment. Single-agent fluoropyrimidine was reported for 22.0% of patients, while 19.5% were treated with irinotecan and a fluoropyrimidine or platinum agent. The most common physician-reported symptoms during second-line treatment were nausea/vomiting (44.7%) and pain (11.3%), with antiemetics (44.7%), analgesics (36.5%), and nutritional support (11.3%) most often used as supportive care. Two-thirds of inpatient hospitalizations were for chemotherapy infusion. Outpatient hospitalization (31.6%) and visits to the oncologist (58.8%) were common among second-line patients.

Conclusion: Most patients received second-line treatment, although regimens varied. Understanding MGC patient characteristics and treatment patterns in South Korea will help address unmet needs.

Keywords: Observational study; Republic of Korea; Resource use; Stomach neoplasms; Treatment patterns.

PubMed Disclaimer

Conflict of interest statement

This study was supported by Eli Lilly and Company. The following authors are employees of Eli Lilly and Company and may own company stock: G.C.C., A.M.L., N.R., R.C., and J.S.K.

Figures

Fig. 1.
Fig. 1.
Physician-reported symptoms (% of patients) by line of therapy. a)Other symptoms or complications included bruises, diarrhea, neuralgia, mucositis, weakness, fatigue, hand numbness, hand-foot reaction, dermatitis, varicella, weakness of whole body, and leukopenia.

References

    1. Bang YJ, Yalcin S, Roth A, Hitier S, Ter-Ovanesov M, Wu CW, et al. Registry of gastric cancer treatment evaluation (REGATE): I baseline disease characteristics. Asia Pac J Clin Oncol. 2014;10:38–52. - PubMed
    1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86. - PubMed
    1. Jung KW, Won YJ, Kong HJ, Oh CM, Cho H, Lee DH, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res Treat. 2015;47:127–41. - PMC - PubMed
    1. Ter-Ovanesov M, Yalcin S, Zalcberg J, Hitier S, Bang YJ, Wu CW, et al. Registry of gastric cancer treatment evaluation (REGATE): II treatment practice. Asia Pac J Clin Oncol. 2013;9:373–80. - PubMed
    1. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83. - PubMed

MeSH terms

LinkOut - more resources